13F Holdings
中文EN

MNPR Monopar Therapeutics

Pharmaceutical Preparations · Nasdaq · SEC CIK 1645469 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-15.3%
ROA-15.0%
ROIC (approx.)-45.6%
Asset turnover—

Leverage & solvency

Liabilities / assets2.4%
Debt / equity0.00x
Current ratio43.55x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0———
R&D expense$9.90M$13.01M$5.60M$7.59M$6.49M
SG&A expense$6.80M$3.16M$3.23M$2.95M$2.63M
Operating income-$16.70M-$16.16M-$8.83M-$10.54M-$9.13M
Pretax income-$13.72M-$15.59M-$8.40M——
Income tax$800$800$800$800$0
Net income-$13.72M-$15.59M-$8.40M-$10.52M-$9.10M
EPS (basic)-1.85-4.11-3.04-0.83-0.73
EPS (diluted)————-0.73
Weighted avg. shares (diluted)————12.47M
Banking
Net interest income——$429,039$21,239$24,024
Balance sheet
Cash & equivalents$61.83M$45.82M$7.27M$8.19M$20.30M
Short-term investments$60.88M$45.53M$6.54M$12.18M—
Current assets$140.46M$60.29M$7.33M$13.17M$20.52M
Total assets$140.72M$60.29M$7.35M$13.23M$20.52M
Current liabilities$2.74M$5.25M$1.76M$3.13M$1.58M
Total liabilities$2.89M$5.25M$1.76M$3.14M$1.58M
Shareholders' equity$137.83M$55.04M$5.59M$10.09M$18.94M
Shares outstanding6.69M6.10M2.98M12.95M12.60M
Cash flow statement
Operating cash flow-$12.20M-$6.40M-$7.86M-$7.23M-$7.32M
Investing cash flow-$63.45M-$14.34M$4.93M-$4.92M$0
Financing cash flow$91.57M$59.29M$2.03M$32,873$10.88M
Stock-based compensation$4.84M$1.14M$1.90M$1.64M$1.47M
Share buybacks$35.00M$0———

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.